Graham Charles Bloomfield

This inventor holds 12 USPTO granted patents and 8 published patent applications and 6 EPO patents. Top assignee: Novartis Ag. Active years: 2010-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Graham Charles Bloomfield. Retrieved from https://idiyas.com/inventor/graham-charles-bloomfield

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 (Patent Applications = 8)

% Patents Active = 66.7

EPO Patents = 6 (Patent Applications = 8)

Average Co-Inventor Count = 9.4

ph-index = 3

Forward Citations = 25(Granted Patents)

Location History:

West Sussex, GB (2010)
Broadbridge Heath, GB (2014)
Horsham, GB (2011 - 2018)

Company Filing History:

12 out of 3,975

Novartis Ag

patents

Years Active: 2010-2018

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10112926 - Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-10-30),

2. 10004732 - Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors (2018-06-26),

3. 9643983 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2017-05-09),

4. 9303035 - Substituted pyrazino[1',2′:1,2]pyrrolo[3,4-d]pyrimidines, pyrimido[4′,5′:3,4]pyrrolo[2,1-c][1,4]oxazines and pyrimido[4′,5′:3,4]pyrrolo[1,2-d][1,4]oxazepines for inhibiting the CFTR channel (2016-04-05),

5. 9139586 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2015-09-22),

6. 8901134 - Pyrazolo [3,4-D] pyrimidine derivatives useful to treat respiratory disorders (2014-12-02),

7. 8697687 - Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives (2014-04-15),

8. 8129541 - 5-phenylthiazole derivatives and use as PI3 kinase inhibitors (2012-03-06),

9. 8039472 - Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel (2011-10-18),

10. 8017608 - 5-Phenylthiazole derivatives and their use as p13 kinase inhibitors (2011-09-13),

11. 7902375 - 5-phenyl-4-methyl-thiazol-2-yl-amine derivatives as inhibitors of phosphatidylin ositol 3 kinase enzymes (PI13) for treatment of inflammatory diseases (2011-03-08),

12. 7687637 - 5-phenylthiazole derivatives and use as Pi3 kinase inhibitors (2010-03-30),

Title: Innovations of Graham Charles Bloomfield

Introduction

Graham Charles Bloomfield is a notable inventor based in Horsham, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 12 patents. His work primarily focuses on developing compounds that target specific biological pathways.

Latest Patents

Among his latest patents are "Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors" and "Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors." Both inventions provide compounds that inhibit the activity of the PI 3-kinase gamma isoform, which is crucial for treating diseases mediated by its activation.

Career Highlights

Graham Bloomfield is currently associated with Novartis AG, a leading global healthcare company. His innovative work has positioned him as a key player in the development of new therapeutic agents.

Collaborations

Throughout his career, Graham has collaborated with esteemed colleagues such as Ian Bruce and Lee Edwards. These partnerships have enhanced the scope and impact of his research.

Conclusion

Graham Charles Bloomfield's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.